688076 Stock Overview
A biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥50.41 |
| 52 Week High | CN¥81.50 |
| 52 Week Low | CN¥35.63 |
| Beta | 0.52 |
| 1 Month Change | -3.24% |
| 3 Month Change | -4.53% |
| 1 Year Change | 16.47% |
| 3 Year Change | 17.95% |
| 5 Year Change | n/a |
| Change since IPO | -34.95% |
Recent News & Updates
Recent updates
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?
Sep 26
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Jun 23Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 04There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump
Mar 04Shareholder Returns
| 688076 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.3% | -1.9% | -1.2% |
| 1Y | 16.5% | -1.8% | 11.8% |
Return vs Industry: 688076 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 688076 exceeded the CN Market which returned 11.8% over the past year.
Price Volatility
| 688076 volatility | |
|---|---|
| 688076 Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688076 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688076's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,779 | n/a | www.sinopep.com.cn |
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates.
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Fundamentals Summary
| 688076 fundamental statistics | |
|---|---|
| Market cap | CN¥11.08b |
| Earnings (TTM) | CN¥421.47m |
| Revenue (TTM) | CN¥1.58b |
26.3x
P/E Ratio7.0x
P/S RatioIs 688076 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688076 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.58b |
| Cost of Revenue | CN¥549.57m |
| Gross Profit | CN¥1.03b |
| Other Expenses | CN¥605.29m |
| Earnings | CN¥421.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 65.14% |
| Net Profit Margin | 26.74% |
| Debt/Equity Ratio | 49.4% |
How did 688076 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:37 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wanhua Wu | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Jiabo Zhang | Guosen Securities Co., Ltd. |